SBP solbec pharmaceuticals limited

iressa fails

  1. skint
    5,858 Posts.
    lightbulb Created with Sketch. 143
    clock Created with Sketch.
    20/12/04
    11:21
    Post #: 723521
    'LONDON (Reuters) - AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer in a major clinical trial, sending its shares down more than 8 percent. '

    This is after a trial of 1692 patients . It failed to do better than the placebo in extending life in NSCLC patients . OSIP , manuf of Tarciva , a drug already proven to extend life in NSCLC jumped 45% on the news , to $US68.38 for a market cap of 3.46B .
    NSCLC is one of the possible targets of Solbecs Coramsine .
    SBP Price at posting: 0.0¢ Sentiment: None Disclosure: Not Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply
 

Featured News

TLM Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW
right-arrow Created with Sketch.
TLX Telix gets its foot in the FDA door bringing prostate cancer detection closer to neglected Americans
right-arrow Created with Sketch.
VMS Venture hits 1,839 TREO at Jupiter in WA with best intersection to date
right-arrow Created with Sketch.
SLS Historical prospects impress Solstice, with 25% copper and significant anomaly
right-arrow Created with Sketch.
NEWS Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market
right-arrow Created with Sketch.
TVN CSIRO backs Tivan's downstream tech for WA vanadium concentrate
right-arrow Created with Sketch.

Top Stories

watchlist Created with Sketch. Add SBP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.